ea0099p266 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024
Ragozzino Giovanni
, Martina Madonna Igea
, Mattera Edi
Background and Aims: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a diagnosis of inclusion relying on a set of metabolic risk factors and the presence of hepatic steatosisis; viscerl obesity, insulin resistance, type 2 diabetes (T2D) may often coexist in MAFLD patients. MAFLD is present in up to 80%f of T2D patients. Pioglidazone, a peroxisome proliferator-activated receptor agonist reduce hepatic/visceral fat (HVF) and improve necroinflammation in liver. Du...